505 filings
8-K
CPRX
Catalyst Pharmaceuticals Inc
8 May 24
Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
4:54pm
10-Q
2024 Q1
CPRX
Catalyst Pharmaceuticals Inc
Quarterly report
8 May 24
4:06pm
ARS
2023 FY
CPRX
Catalyst Pharmaceuticals Inc
10 Apr 24
Annual report to shareholders
4:25pm
DEF 14A
CPRX
Catalyst Pharmaceuticals Inc
Definitive proxy
10 Apr 24
4:23pm
8-K
CPRX
Catalyst Pharmaceuticals Inc
13 Mar 24
Available in the U.S. by Prescription for Patients Aged Two Years and Older
5:01pm
8-K
wze4gik5wfboo
28 Feb 24
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
8:37pm
8-K
zicxe5if5205
21 Feb 24
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD
4:34pm
8-K
888bnyj0mhq
9 Jan 24
Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering of Common Stock
5:15pm
8-K
rec0dnmprx6zu
8 Jan 24
Regulation FD Disclosure
8:10am
8-K
85m apr5u
5 Jan 24
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
5:23pm
424B5
q2xo 2a7lxca
5 Jan 24
Prospectus supplement for primary offering
5:15pm
424B5
1izubws421c8
4 Jan 24
Prospectus supplement for primary offering
6:24pm
8-K
ji8yh98 tg6cw
19 Dec 23
Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo Pharma
4:30pm
S-8
hghn4ym6ds qk
8 Dec 23
Registration of securities for employees
4:31pm
S-8
upp2vidk
8 Dec 23
Registration of securities for employees
4:31pm
8-K
vr9 dyn7u4mzxxlbdt
7 Dec 23
Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions
4:30pm
8-K
rhkqg
8 Nov 23
Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update
4:35pm
8-K
c9b8k03k 3y8
3 Nov 23
New Patents Further Reinforce the FIRDAPSE® (amifampridine) Intellectual Patent Portfolio
4:30pm